title: Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass.
abstract: Several studies have evaluated the role of inflammation in type 1 diabetes (T1D). The safety profile and anti-inflammatory properties of high dose omega-3 fatty acids combined with Vitamin D supplementation make this therapy a possible candidate for T1D intervention trials. Herein, we describe the case of a 14-year-old boy with new onset T1D treated with high dose Omega-3 and vitamin D3. By 12 months, peak C-peptide increased to 0.55 nmol/L (1.66 ng/mL) corresponding to a 20% increment from baseline and AUC C-peptide was slightly higher compared to 9 months (0.33 vs. 0.30 nmol/L/min) although remaining slightly lower than baseline. Combination high-dose Omega-3 fatty acids and high-dose vitamin D3 therapy was well tolerated and may have beneficial effects on beta-cell function. Randomized controlled trials could be of assistance to determine whether this therapy may result in the preservation of beta-cell function in patients with new onset T1D.
authors.affiliation: Diabetes Research Institute, Clinical Cell Transplant Program, University of Miami, Miami, FL, USA. dbaidal@med.miami.edu.
authors.forename: D A
authors.initials: DA
authors.lastname: Baidal
authors.forename: C
authors.initials: C
authors.lastname: Ricordi
authors.forename: M
authors.initials: M
authors.lastname: Garcia-Contreras
authors.forename: A
authors.initials: A
authors.lastname: Sonnino
authors.forename: A
authors.initials: A
authors.lastname: Fabbri
mesh_terms: D000293:Adolescent; D001402:B-Lymphocytes / Q000187:drug effects / Q000502:physiology; D002096:C-Peptide / Q000378:metabolism*; D002762:Cholecalciferol / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D008297:Male; D016896:Treatment Outcome
chemical_list: D002096:C-Peptide; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D002762:Cholecalciferol